Scholarlink

Background <p>Respiratory syncytial virus (RSV) can lead to serious respiratory illnesses in both children and adults, particularly affecting older individuals and those with chronic health issues. Due to its symptoms resembling other respiratory viruses and irregular RSV standard-of-care testing, RSV cases in adults frequently remain unreported.</p> Methods <p>We retrospectively estimated the incidence of hospitalisations and deaths attributable to RSV in adults in Norway using a time-series model-based approach. Data were obtained from the Norwegian Patient Registry and Norwegian Cause of Death Registry to estimate RSV-attributable hospitalisations and deaths, respectively, among adults from 2010 to 2019. A quasi-Poisson time-series regression model was applied to estimate RSV annual (age- and risk-stratifications) hospitalisation incidence rates (IRs) and mortality rates (per 100,000 person-years).</p> Results <p>Annual RSV-attributable hospitalisation IRs for adults aged ≥ 65 years with risk factors were 289–517 for cardiorespiratory, 243–434 for cardiovascular, and 178–318 per 100,000 person-years for respiratory hospitalisations. RSV-attributable hospitalisations represented 1–3% of total cardiorespiratory hospitalisations. Adults aged 18–44 years with risk factors had similar rates as those aged ≥ 65 years without risk factors. RSV-attributable mortality rates for adults aged ≥ 65 years were 19–35 for cardiorespiratory, 11–19 for respiratory, and 10–18 per 100,000 person-years for cardiovascular deaths. RSV-attributable deaths accounted for 1–5% of total cardiorespiratory deaths.</p> Conclusions <p>RSV significantly contributes to hospitalisations and deaths in adults in Norway, particularly among older adults and younger adults with underlying diseases. The introduction of RSV vaccines can have a substantial public health impact in reducing the burden of RSV-attributable cardiovascular and respiratory events.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Estimated Incidence of Hospitalisations and Deaths Attributable to Respiratory Syncytial Virus Infections in Adults in Norway between 2010 and 2019: A Time-Series Modelling Study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年8月14日

查看全文
  • Maribel Casas,
  • Caihua Liang,
  • Tor Molden,
  • Robin Bruyndonckx,
  • Mikel Esnaola,
  • Somsuvro Basu,
  • Worku Biyadgie Ewnetu,
  • Pimnara Peerawaranun,
  • Solomon Molalign Moges,
  • Bradford D. Gessner,
  • Aleksandra Polkowska-Kramek,
  • Elizabeth Begier

摘要

Background

Respiratory syncytial virus (RSV) can lead to serious respiratory illnesses in both children and adults, particularly affecting older individuals and those with chronic health issues. Due to its symptoms resembling other respiratory viruses and irregular RSV standard-of-care testing, RSV cases in adults frequently remain unreported.

Methods

We retrospectively estimated the incidence of hospitalisations and deaths attributable to RSV in adults in Norway using a time-series model-based approach. Data were obtained from the Norwegian Patient Registry and Norwegian Cause of Death Registry to estimate RSV-attributable hospitalisations and deaths, respectively, among adults from 2010 to 2019. A quasi-Poisson time-series regression model was applied to estimate RSV annual (age- and risk-stratifications) hospitalisation incidence rates (IRs) and mortality rates (per 100,000 person-years).

Results

Annual RSV-attributable hospitalisation IRs for adults aged ≥ 65 years with risk factors were 289–517 for cardiorespiratory, 243–434 for cardiovascular, and 178–318 per 100,000 person-years for respiratory hospitalisations. RSV-attributable hospitalisations represented 1–3% of total cardiorespiratory hospitalisations. Adults aged 18–44 years with risk factors had similar rates as those aged ≥ 65 years without risk factors. RSV-attributable mortality rates for adults aged ≥ 65 years were 19–35 for cardiorespiratory, 11–19 for respiratory, and 10–18 per 100,000 person-years for cardiovascular deaths. RSV-attributable deaths accounted for 1–5% of total cardiorespiratory deaths.

Conclusions

RSV significantly contributes to hospitalisations and deaths in adults in Norway, particularly among older adults and younger adults with underlying diseases. The introduction of RSV vaccines can have a substantial public health impact in reducing the burden of RSV-attributable cardiovascular and respiratory events.